FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
Links shared publicly online about this topic.
- 1,782total visits
FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
View full resource at drugs.com
Tags: Urinary System, Organ Transplantation, Heart Transplant, Kidney Transplant, Disease and Condition, Children's Health, FDA, Transplantation
Most Recently Shared on August 31, 2009 at 8:32 pm By:
FDA Approves Valcyte to Prevent Cytomegalovirus (CMV) Disease in Pediatric Transplant Patients - http://bit.ly/6TUXY
Anti-CMV Drug Cleared for Pediatric Transplant Patients - Renal and Urology News
renalandurologynews.com — “The FDA has approved Valcyte (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant recipients (aged four months to 16 years) who are at high risk of developing the disease. FDA also approved a new pediatric oral solution formulation for the drug that will enable easier administration to these patients.” View full resource at renalandurologynews.com
Most Recently Shared on October 16, 2009 at 6:38 pm By:
Renal Urology News Urology, Medical Publisher, Health News, and Nephrology
Anti-CMV Drug Cleared for Pediatric Transplant Patients: The FDA has approved Valcyte (valganciclovir hydrochlor.. http://bit.ly/10QxhC
Advertisement
